|Bid||0.5100 x 4000|
|Ask||0.5931 x 1400|
|Day's Range||0.5200 - 0.6307|
|52 Week Range||0.4000 - 2.3900|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Some of the losses seen by insiders who purchased US$212k worth of Cidara Therapeutics, Inc. ( NASDAQ:CDTX ) shares...
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed that the application filing of lead antifungal drug rezafungin as a potential first-line treatment for candidemia and invasive candidiasis remains on track for mid-2022, which HC Wainwright takes to mean as late as August. HC Wainwright lowered the price target to $6 from $7.50, citing the challenging capi
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?